Sonoma Pharmaceuticals, Inc. (SNOA) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Sonoma Pharmaceuticals, Inc. (SNOA) closed at USD 1.16 on 2026-10-14, a change of -69.7 % over the past year, with a market capitalization of USD 5.51M.

Sonoma Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sonoma Pharmaceuticals, Inc. key figures

Previous close

USD 1.16 (2026-10-14)

1-year change

-69.7 %

Market cap

USD 5.51M

Enterprise value

USD 907,688

P/E ratio (trailing)

-0.96

P/E ratio (forward)

-2.05

EPS (trailing)

-1.20

EPS (forward)

-0.56

PEG ratio

1.08

Price to book

0.83

Revenue growth

59.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.13

Employees

10

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sonoma Pharmaceuticals, Inc. and compare it with other stocks.